188 related articles for article (PubMed ID: 34680073)
1. Immunoprofiles and DNA Methylation of Inflammatory Marker Genes in Ulcerative Colitis-Associated Colorectal Tumorigenesis.
Mäki-Nevala S; Ukwattage S; Wirta EV; Ahtiainen M; Ristimäki A; Seppälä TT; Lepistö A; Mecklin JP; Peltomäki P
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680073
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.
Mäki-Nevala S; Ukwattage S; Olkinuora A; Almusa H; Ahtiainen M; Ristimäki A; Seppälä T; Lepistö A; Mecklin JP; Peltomäki P
Int J Cancer; 2021 Jun; 148(12):2997-3007. PubMed ID: 33521965
[TBL] [Abstract][Full Text] [Related]
3. Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC.
Scarpa M; Scarpa M; Castagliuolo I; Erroi F; Kotsafti A; Basato S; Brun P; D'Incà R; Rugge M; Angriman I; Castoro C
Oncotarget; 2016 Mar; 7(9):10322-31. PubMed ID: 26862732
[TBL] [Abstract][Full Text] [Related]
4. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias.
Konishi K; Shen L; Wang S; Meltzer SJ; Harpaz N; Issa JP
Gastroenterology; 2007 Apr; 132(4):1254-60. PubMed ID: 17408633
[TBL] [Abstract][Full Text] [Related]
5. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers.
An B; Kondo Y; Okamoto Y; Shinjo K; Kanemitsu Y; Komori K; Hirai T; Sawaki A; Tajika M; Nakamura T; Yamao K; Yatabe Y; Fujii M; Murakami H; Osada H; Tani T; Matsuo K; Shen L; Issa JP; Sekido Y
Int J Cancer; 2010 Nov; 127(9):2095-105. PubMed ID: 20131317
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors.
Abouzeid HE; Kassem AM; Abdel Wahab AH; El-mezayen HA; Sharad H; Abdel Rahman S
Tumour Biol; 2011 Oct; 32(5):845-52. PubMed ID: 21274674
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.
Mäki-Nevala S; Valo S; Ristimäki A; Sarhadi V; Knuutila S; Nyström M; Renkonen-Sinisalo L; Lepistö A; Mecklin JP; Peltomäki P
EBioMedicine; 2019 Jan; 39():280-291. PubMed ID: 30578081
[TBL] [Abstract][Full Text] [Related]
9. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
10. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.
Tahara T; Yamamoto E; Madireddi P; Suzuki H; Maruyama R; Chung W; Garriga J; Jelinek J; Yamano HO; Sugai T; Kondo Y; Toyota M; Issa JP; Estécio MR
Gastroenterology; 2014 Feb; 146(2):530-38.e5. PubMed ID: 24211491
[TBL] [Abstract][Full Text] [Related]
11. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
[TBL] [Abstract][Full Text] [Related]
12. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
13. Host genetic factors, related to inflammatory response, influence the CpG island methylation status in colonic mucosa in ulcerative colitis.
Tahara T; Shibata T; Nakamura M; Okubo M; Yamashita H; Yoshioka D; Yonemura J; Kmiya Y; Ishizuka T; Fujita H; Nagasaka M; Yamada H; Hirata I; Arisawa T
Anticancer Res; 2011 Mar; 31(3):933-8. PubMed ID: 21498716
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa.
Krakowczyk L; Strzelczyk JK; Adamek B; Zalewska-Ziob M; Arendt J; Półtorak S; Maciejewski B; Wiczkowski A
Med Sci Monit; 2008 Oct; 14(10):BR219-25. PubMed ID: 18830187
[TBL] [Abstract][Full Text] [Related]
15. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
16. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
17. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive DNA Methylation Profiling of Inflammatory Mucosa in Ulcerative Colitis.
Tahara T; Hirata I; Nakano N; Nagasaka M; Nakagawa Y; Shibata T; Ohmiya N
Inflamm Bowel Dis; 2017 Jan; 23(1):165-173. PubMed ID: 27930411
[TBL] [Abstract][Full Text] [Related]
19. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
20. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.
Alonso S; Dai Y; Yamashita K; Horiuchi S; Dai T; Matsunaga A; Sánchez-Muñoz R; Bilbao-Sieyro C; Díaz-Chico JC; Chernov AV; Strongin AY; Perucho M
Oncotarget; 2015 Feb; 6(5):3420-31. PubMed ID: 25638164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
